AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 293 min read$SYK

Stryker: Q3 Earnings Snapshot

Stryker Corp. (SYK) reported Q3 profit of $753M, or $1.96 per share, missing analyst estimates of $3.56 per share. Revenue was $6.52B, also below expectations. The company forecasts full-year earnings of $14.80-$14.90 per share, according to Zacks Investment Research.

Original reporting
finance.yahoo.com
Published Oct 29, 2026, 8:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Stryker: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$SYKBearishMed
01

Why it matters

Because it includes both the quarter’s EPS/revenue versus expectations and a specific full-year EPS range, it can drive immediate earnings estimate revisions and near-term positioning in SYK.

02

Market read

Traders can update SYK’s earnings expectations using the reported Q3 miss and the stated FY EPS range.

03

What to watch

The article does not break out segment performance, margins, or cash flow, so traders may overreact to headline EPS/revenue without knowing the underlying drivers.

Relevance 8/10Novelty 7/10Timing: reported Thursday after the quarter closed, before/around the next trading session

Background

The piece is an AP-generated earnings snapshot for Stryker’s Q3 results, referencing Zacks consensus estimates.

Company-level read

Ticker impact

$SYKBearishMedium confidence
Context

Stryker reported Q3 profit of $1.96 per share and adjusted EPS of $3.52, both below Zacks/Street expectations, and guided FY EPS to $14.80-$14.90.

Expected impact

Likely downward pressure as the market digests the EPS and revenue misses and compares the FY guidance range to expectations.

Evidence & confidence

The article provides the company’s own Q3 EPS and revenue versus consensus and a specific full-year EPS range, which are direct inputs to earnings revisions and valuation.

Market effects

Sector

A large medical device name missing on EPS and revenue can weigh on near-term sentiment for medtech earnings momentum, though the article does not provide sector-wide data.

Regional

Limited, primarily affects US medtech sentiment rather than a broad regional macro move.

Global

Moderate for global medtech sentiment due to Stryker’s scale, but no cross-border catalysts are mentioned.

Counterpoint

What could challenge this read

The guidance range is still provided and may be viewed as stable or acceptable if investors expected a larger cut; the miss could be partially offset by confidence in full-year delivery.

Key entities

  • company
    Stryker Corp.

    Medical device maker reporting Q3 profit, adjusted EPS, revenue, and full-year earnings guidance.

  • research_consensus
    Zacks Investment Research

    Provides the analyst consensus estimates cited in the article for EPS and revenue.

Read at source← All news

StoryStryker cuts FY 2026 outlook after Q3 miss and operational setbacks

Also covered by

4 outlets

Related articles

OCT 30
$SYKHighAI 8/10

Piper Sandler cuts Stryker stock price target on Q3 miss

Piper Sandler reduced its price target for Stryker (NYSE:SYK) to $325 from $390 after Q3 results missed expectations. The company lowered its full-year guidance, citing deceleration in the large joint market. Shares are down 24% from their 52-week high. Multiple analysts have adjusted their targets and ratings following the earnings report.

investing.com2 min
OCT 30
$SYKMedAI 8/10

Stryker (SYK) Q3 2026 Earnings Call Transcript

Stryker (SYK) reported Q3 2026 earnings, with organic sales growth of 7.7% and adjusted EPS of $3.52. The company faced delays in new product sales due to a cyber incident and SAP implementation but remains confident in long-term growth. Stryker updated its guidance, expecting similar Q4 growth. Recent acquisitions include ZuriMED and an investment in CMR Surgical. Vascular business showed sequential improvement, and the company anticipates commercializing AVS' IVL platform in 2027.

finance.yahoo.com8 min
OCT 30
$SYKHighAI 9/10

Stryker lowers 2026 guidance after slowdown in hip, knee procedures

Stryker reported Q3 revenue of $6.5B, up 7.7% YoY, but net earnings fell 12.3% YoY. CEO Kevin Lobo cited a market slowdown in hip and knee procedures due to economic challenges. The company lowered its 2026 sales guidance to 6.5-7.0% from 8.3-9.3%. Lobo will step down as CEO at year-end, succeeded by COO Spencer Stiles. Stryker also invested $400M in CMR Surgical for U.S. distribution rights.

finance.yahoo.com2 min